Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Durvalumab + Oleclumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 66||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).|
|Oleclumab||MEDI9447||Adenosine Targeting 16 CD73 Antibody 6||Oleclumab (MEDI9447) is a monoclonal antibody against NT5E (CD73), resulting in activation of an anti-tumor immune response by preventing the conversion of AMP to adenosine in the tumor microenvironment (PMID: 27622077).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03819465||Phase I||Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed Disodium Nab-paclitaxel AZD9150 + Durvalumab Cisplatin Durvalumab||A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN)||Recruiting|
|NCT03773666||Phase I||Durvalumab + Oleclumab Durvalumab||A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)||Recruiting|
|NCT04262375||Phase II||Durvalumab + Oleclumab||A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION)||Not yet recruiting|
|NCT04262388||Phase II||Durvalumab + Oleclumab||A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME)||Not yet recruiting|
|NCT03822351||Phase II||Durvalumab Durvalumab + Monalizumab Durvalumab + Oleclumab||Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)||Active, not recruiting|
|NCT03794544||Phase II||Durvalumab + Oleclumab AZD9150 + Durvalumab Durvalumab Durvalumab + Monalizumab||Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer||Recruiting|